Manyau Maudy C P, Zambuko Blessing, Chatambudza Moses, Zhou Danai T, Manasa Justen
Laboratory Diagnostic and Investigative Sciences, University of Zimbabwe, Harare, Zimbabwe.
Biomedical Research and Training Institute, Harare, Zimbabwe.
Oncol Rev. 2024 Apr 19;18:1375291. doi: 10.3389/or.2024.1375291. eCollection 2024.
Diffuse large B-cell lymphoma (DLBCL) accounts for half of non-Hodgkin lymphoma cases in people living with human immunodeficiency syndrome (PLWH). The interplay of viremia, immune dysregulation and co-infection with oncogenic viruses play a role in pathogenesis of DLBCL in PLWH (HIV-DLBCL). This scoping review aimed to describe the molecular landscape of HIV-DLBCL, investigate the impact of biomarker on clinical outcomes and describe technologies used to characterise HIV-DLBCL. Thirty-two papers published between 2001 and 2023 were included in this review. Samples of HIV-DLBCL were relatively small (16-110). Cohort effects influenced frequencies of molecular characteristics hence their impact on survival was not clear. Molecular features were distinct from HIV-unrelated DLBCL. The most frequently assessed characteristic was cell of origin (81.3% of studies). Somatic mutations were the least researched (6.3% of studies). Overall, biomarker identification in HIV-DLBCL requires broader richer data from larger or pooled samples using more powerful techniques such as next-generation sequencing.
弥漫性大B细胞淋巴瘤（DLBCL）占人类免疫缺陷病毒感染者（PLWH）中非霍奇金淋巴瘤病例的一半。病毒血症、免疫失调以及与致癌病毒的共同感染之间的相互作用在PLWH（HIV-DLBCL）的DLBCL发病机制中发挥作用。本综述旨在描述HIV-DLBCL的分子格局，研究生物标志物对临床结局的影响，并描述用于表征HIV-DLBCL的技术。本综述纳入了2001年至2023年间发表的32篇论文。HIV-DLBCL的样本相对较小（16 - 110个）。队列效应影响分子特征的频率，因此其对生存的影响尚不清楚。分子特征与非HIV相关的DLBCL不同。最常评估的特征是细胞起源（81.3%的研究）。体细胞突变的研究最少（6.3%的研究）。总体而言，HIV-DLBCL中的生物标志物识别需要使用更强大的技术（如下一代测序）从更大或汇总样本中获取更广泛、更丰富的数据。
